Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
A high concentration medical-grade polydeoxyribonucleotide (PDRN) formulation designed for advanced skin rejuvenation.
-
Transition brings enhanced patient experience and Botox, lip filler, and other med spa treatments.
-
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being...
-
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
-
Castle today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.
-
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
-
Castle announced the publication of a validation study in the Journal of the American Academy of Dermatology for its AdvanceAD-Tx test.
-
Miami, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The 2026 South Beach Symposium (SBS) and Masters of Pediatric Dermatology (MOPD) wrapped up their annual meetings in Miami Beach from Thursday, Feb. 5...
-
The current indications of soficitinib under development are strategically positioned within the vast dermatology market.
-
Laseroptek America Corp. today announced that it has filed counterclaims and third-party claims against Strata Skin Science